statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	477
IT - Italia	178
SG - Singapore	163
CN - Cina	85
VN - Vietnam	65
BR - Brasile	56
DE - Germania	32
KR - Corea	31
FR - Francia	30
HK - Hong Kong	30
IN - India	30
SE - Svezia	24
NL - Olanda	23
FI - Finlandia	13
MA - Marocco	13
PL - Polonia	13
TR - Turchia	13
IE - Irlanda	10
AR - Argentina	9
BD - Bangladesh	9
RO - Romania	9
RU - Federazione Russa	9
AU - Australia	8
GB - Regno Unito	8
MX - Messico	8
ZA - Sudafrica	8
AT - Austria	7
JP - Giappone	7
CA - Canada	6
ID - Indonesia	5
IR - Iran	5
PH - Filippine	5
EC - Ecuador	4
EG - Egitto	4
IQ - Iraq	4
BE - Belgio	3
ES - Italia	3
JO - Giordania	3
PK - Pakistan	3
BG - Bulgaria	2
BO - Bolivia	2
CH - Svizzera	2
CL - Cile	2
CO - Colombia	2
DZ - Algeria	2
GR - Grecia	2
LB - Libano	2
SA - Arabia Saudita	2
SK - Slovacchia (Repubblica Slovacca)	2
TW - Taiwan	2
UZ - Uzbekistan	2
AE - Emirati Arabi Uniti	1
BB - Barbados	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
GE - Georgia	1
IL - Israele	1
KG - Kirghizistan	1
LK - Sri Lanka	1
LT - Lituania	1
LV - Lettonia	1
MD - Moldavia	1
MY - Malesia	1
NP - Nepal	1
OM - Oman	1
PE - Perù	1
PT - Portogallo	1
SI - Slovenia	1
UA - Ucraina	1
VE - Venezuela	1
Totale	1.457

Nome	#
Glypican 1-targeted therapeutic approaches adopting doxorubicin-loaded chitosan nanobubbles and antibody-based strategy in the context of Pancreatic Ductal Adenocarcinoma	337
A novel epigenetic machine learning model to define risk of progression for hepatocellular carcinoma patients	163
A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma	154
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies	148
The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells.	141
Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma	136
New insight into therapies targeting angiogenesis in hepatocellular carcinoma	136
The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma	110
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies	83
Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer	79
Totale	1.487

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	11	0	0	0	0	0	0	0	0	0	0	0	11
2021/2022	43	3	0	3	0	0	0	0	1	1	1	1	33
2022/2023	115	4	12	5	13	18	18	0	16	17	4	3	5
2023/2024	98	17	6	5	4	4	10	17	18	1	6	10	0
2024/2025	377	9	10	11	41	19	36	27	31	37	47	56	53
2025/2026	843	113	38	134	104	75	50	109	31	100	89	0	0
Totale													1.487

ArTS Archivio della ricerca di Trieste